Ono Pharma Taiwan

Ono Pharma Taiwan is the Taiwanese subsidiary of the Japanese pharmaceutical company Ono Pharmaceutical Co., Ltd., established in December 2014. Headquartered in Taipei, the company is dedicated to the clinical development and commercialization of innovative medicines to meet unmet medical needs in Taiwan. Its primary focus lies in oncology, immunology, and specialty care, notably managing the blockbuster immunotherapy Opdivo (nivolumab) in the region. The company also markets therapies for cancer cachexia and B-cell malignancies, while maintaining strategic partnerships for metabolic and cardiovascular treatments. Ono Pharma Taiwan serves as a critical hub for the parent company's expansion into the broader Asian market outside of Japan.